帕金森病患者血清短链脂肪酸及其与运动和非运动症状的相关性。
Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson's disease patients.
机构信息
Department of Pharmacy, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.
Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.
出版信息
BMC Neurol. 2022 Jan 7;22(1):13. doi: 10.1186/s12883-021-02544-7.
BACKGROUND
Parkinson's disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson's symptoms.
METHODS
50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson's symptoms and the potential effects of medications on the serum SCFAs was analyzed.
RESULTS
Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson's Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid.
CONCLUSIONS
Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson's symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis.
背景
帕金森病（PD）与肠神经系统功能障碍和肠道微生物群落失调有关。短链脂肪酸（SCFAs）来源于肠道微生物群，据推测通过脊髓和迷走神经或循环系统的途径来预测 PD 的发病机制。然而，PD 患者血清中 SCFAs 的浓度知之甚少。本研究旨在探讨 PD 患者 SCFAs 的确切水平及其与帕金森病症状的相关性。
方法
招募了 50 名 PD 患者和 50 名健康对照者，并收集了他们的人口统计学和临床特征。使用气相色谱-质谱联用仪检测血清 SCFAs 浓度。比较 PD 组和对照组之间的 SCFAs。分析血清 SCFAs 与帕金森病症状的相关性，以及药物对血清 SCFAs 的潜在影响。
结果
与对照组相比，PD 患者血清中的丙酸、丁酸和己酸水平较低，而庚酸水平较高。然而，只有血清丙酸水平与统一帕金森病评定量表（UPDRS）第三部分评分（R=-0.365，P=0.009）、简易精神状态检查（MMSE）评分（R=-0.416，P=0.003）和汉密尔顿抑郁量表（HAMD）评分（R=0.306，P=0.03）呈负相关。其他血清 SCFAs 与运动并发症之间无相关性。使用苯海索或替扎尼定增加了血清丙酸浓度。
结论
PD 患者的血清 SCFAs 发生改变，血清丙酸水平的降低与运动症状、认知能力和非抑郁状态相关。因此，肠道微生物衍生的 SCFAs 可能通过血液循环影响帕金森病症状。丙酸补充可能改善 PD 患者的运动和非运动症状，但需要临床试验来验证这一假设。
Zotero 插件